Cytokinetics Inc (NASDAQ:CYTK)

CAPS Rating: 3 out of 5

A biopharmaceutical company, focused on developing small molecule therapeutics for the treatment of cardiovascular diseases and cancer.

Recs

1
Player Avatar TMFBlacknGold (99.40) Submitted: 6/28/2012 11:22:29 PM : Underperform Start Price: $0.64 CYTK Score: -60.74

With a fair book value of $0.54 this could be a dangerous red thumb. However, seeing as the company is losing tons of money each quarter it seems unlikely that this is a poor long term pick for the gutter.

Featured Broker Partners


Advertisement